Infinity Pharmaceuticals Inc. [INFI] stock is up 19.77 while the S&P 500 has risen 0.39% on Thursday, 11/19/20. While at the time of this article, INFI ATR is sitting at 0.16, with the beta value at 2.03. This stock’s volatility for the past week remained at 16.99%, while it was 10.72% for the past 30-day period. INFI has risen $0.35 from the previous closing price of $1.77 on volume of 2.01 million shares.
On 17, November 2020, Infinity Pharmaceuticals Announces Presentations at the 2020 San Antonio Breast Cancer Symposium. According to news published on Yahoo Finance, Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced two poster presentations featuring clinical data from ongoing studies evaluating eganelisib in triple negative breast cancer (TNBC) at the upcoming San Antonio Breast Cancer Symposium (SABCS) being held virtually, December 8-11, 2020.
Analyst Birdseye View:
The most recent analyst activity for Infinity Pharmaceuticals Inc. [NASDAQ:INFI] stock was on January 04, 2019, when it was Initiated with a Buy rating from B. Riley FBR, which also raised its 12-month price target on the stock to $3. On November 12, 2018, Wells Fargo Downgrade a Market perform rating. On November 12, 2018, JP Morgan Downgrade an Underweight rating. On October 12, 2017, Wells Fargo Upgrade an Outperform rating. On August 10, 2016, Wedbush Reiterated a Neutral rating and boosted its amount target on this stock to $1. On June 15, 2016, Wells Fargo Downgrade a Market perform rating. On June 15, 2016, RBC Capital Mkts Downgrade a Sector perform rating and improved its amount target to $2.
In the past 52 weeks of trading, this stock has oscillated between a low of $0.60 and a peak of $1.87. Right now, the middling Wall Street analyst 12-month amount mark is $3.00. At the most recent market close, shares of Infinity Pharmaceuticals Inc. [NASDAQ:INFI] were valued at $2.12. According to the average price forecast, investors can expect a potential return of 16.67%.
Infinity Pharmaceuticals Inc. [NASDAQ:INFI] most recently reported quarterly sales of 496.0 million, which represented growth of 66.70%. This publicly-traded organization’s revenue is $121,960 per employee, while its income is -$1,882,280 per employee. This company’s Gross Margin is currently 39.80%, its Pretax Margin is -1545.13, and its Net Margin is -1543.36. Continuing to look at profitability, this corporation’s Return on Assets, Equity, Whole Principal & invested Principal is sitting at -86.16, -156.37, -99.14 and -102.59 respectively.
If looking now at the Principal structure of this organization, it shows its whole liability to the whole Principal at 80.52 and the whole liability to whole assets at 65.15. It shows enduring liability to the whole principal at 79.56 and enduring liability to assets at 0.64 while looking for an extended time period.
Readers are usually of view to make a close observation to the indicators that support and make resistance before moving to any particular stock. As of now, the company’s stock is sitting at 1.88 points at 1st support level, the second support level is making up to 1.64. But as of 1st resistance point, this stock is sitting at 2.25 and at 2.38 for 2nd resistance point.
Infinity Pharmaceuticals Inc. [INFI] reported its earnings at -$0.16 per share in the fiscal quarter closing of 9/29/2020. The Analysts for Wall Street were expecting to report its earnings at -$0.16/share signifying the difference of 0 and 0.00% surprise value. Comparing the previous quarter ending of 6/29/2020, the stated earnings were -$0.16 calling estimates for -$0.19/share with the difference of 0.03 depicting the surprise of 15.80%.
Important Ratio’s To Watch
Meanwhile, turning our focus to liquidity, the Current Ratio for Infinity Pharmaceuticals Inc. [NASDAQ:INFI] is 4.40. Likewise, the Quick ratio is also the same, showing Cash ratio at 4.38. Now if looking for a valuation of this stock’s amount to sales ratio it’s 17.94 and it’s amount to book ratio is 7.09.